Welcome to LookChem.com Sign In|Join Free
  • or
Protoporphyrin IX, a cyclic tetrapyrrole belonging to the porphyrin family, is the iron-free form of hemin and exhibits amphiphilic properties. It serves as a precursor to heme in its biosynthetic pathway and consists of porphyrin with four methyl substituents at positions 3, 8, 13, and 17, two vinyl substituents at positions 7 and 12, and two 2-carboxyethyl substituents at positions 2 and 18.

553-12-8

Post Buying Request

553-12-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

553-12-8 Usage

Uses

Used in Analytical Chemistry:
Protoporphyrin IX is used as a standard in protoporphyrin assays for accurate measurement and quantification of protoporphyrin levels in various samples.
Used in Spectroscopy:
It is utilized in fluorescence spectra analysis to study the properties and behavior of protoporphyrin IX under different conditions, which can be useful for understanding its interactions and potential applications.
Used in Cell Culture Studies:
Protoporphyrin IX is employed to treat cells in cell culture to investigate heme-mediated ferroportin 1 transcription, which can provide insights into the regulation of iron homeostasis and related cellular processes.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, Protoporphyrin IX is also known for its use in photodynamic therapy (PDT) for the treatment of various types of cancer. It is used as a photosensitizer, which, when activated by light, generates reactive oxygen species that can destroy cancer cells.
Used in Medical Research:
Protoporphyrin IX is used in the study of heme biosynthesis, iron metabolism, and related disorders, such as porphyria. Understanding its role in these processes can lead to the development of new therapeutic strategies for treating these conditions.

Biochem/physiol Actions

Protoporphyrin IX?levels are elevated in?tumor?cells due to?metabolism anomalies?compared to normal?cells.

Enzyme inhibitor

This iiron-free, immediate precusor of heme (FWfree-acid = 562.67 g/mol; CAS 553-12-8; brownish-yellow solid; soluble in a number of organic solvents; disodium and dipotassium salts solublized in the presence of Tween 80) has lmax values in 25% HCl are 602.4, 582.2, and 557.2 nm. Protoporphryrin IX is also an activator of guanylate cyclase. See also Iron Protoporphyrin IX; Heme; Hemin Target(s): aminolevulinate aminotransferase; 5-aminolevulinate synthase; glutamate: glyoxylate aminotransferase; glutathione S-transferase; glyoxalase I, or lactoylglutathione lyase; guanylate cyclase; heme oxygenase; hydroxymethylbilane synthase, or porphobilinogen deaminase; nitric-oxide synthase; porphobilinogen synthase, or 5-aminolevulinate dehydratase; succinyl-CoA synthetase; tryptophan pyrrolase, or tryptophan 2,3-dioxygenase; and uroporphyrinogen decarboxylase.

Purification Methods

Protoporphyrin IX (3,18-divinyl-2,7,13,17-tetramethylporphin-8,12-dipropionic acid, ooporphyrin) [553-12-8] M 562.7, pKEst ~ 4.8. Protoporphyrin IX is purified by dissolving (4g) in 98-100% HCOOH (85mL), diluting with dry Et2O (700mL) and keeping at 0o overnight. The precipitate is collected and washed with Et2O, then H2O, and dried in a vacuum at 50o over P2O5. It crystallises from aqueous pyridine and from Et2O in monoclinic, brownish-yellow prisms. The UV max values in 25% HCl are 557.2, 582.2 and 602.4nm. It is freely soluble in ethanolic HCl, AcOH, CHCl3, and Et2O containing AcOH. It forms sparingly soluble diNa and diK salts. [Ramsey Biochemical Preparations 3 39 1953, UV: Holden Aust J. Exptl Biol and Med Sci 15 412 1937, Garnick J Biol Chem 175 333 1948, IR: Falk & Willis Aust J Sci Res [A] 4 579 1951, Beilstein 26 IV 3042.]

Toxicity evaluation

protoporphyrin IX, is highly toxic in the presence of light and molecular oxygen, killing photosynthetic plants very quickly through the generation of singlet oxygen.

Check Digit Verification of cas no

The CAS Registry Mumber 553-12-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,5 and 3 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 553-12:
(5*5)+(4*5)+(3*3)+(2*1)+(1*2)=58
58 % 10 = 8
So 553-12-8 is a valid CAS Registry Number.
InChI:InChI=1/C34H34N4O4/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25/h7-8,13-16,35-36H,1-2,9-12H2,3-6H3,(H,39,40)(H,41,42)/b25-13u,26-13-,27-14-,28-15u,29-14u,30-15-,31-16u,32-16-

553-12-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name protoporphyrin

1.2 Other means of identification

Product number -
Other names Protoporphyrin IX

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:553-12-8 SDS

553-12-8Synthetic route

protoporphyrin IX dimethyl ester
5522-66-7

protoporphyrin IX dimethyl ester

protoporphyrin IX
553-12-8

protoporphyrin IX

Conditions
ConditionsYield
With potassium hydroxide In methanol Reflux; Inert atmosphere; Darkness;76.6%
With hydrogenchloride In water
With zinc diacetate In methanol; dichloromethane; chloroform; water
harderoporphyrinogen IX
7412-77-3

harderoporphyrinogen IX

protoporphyrin IX
553-12-8

protoporphyrin IX

Conditions
ConditionsYield
With 1H-imidazole; Bacillus subtilis protoporphyrinogen oxidase; flavin adenine dinucleotide In phosphate buffer; dimethyl sulfoxide at 25℃; pH=7.4; Enzyme kinetics; Further Variations:; Reagents;
hemin

hemin

protoporphyrin IX
553-12-8

protoporphyrin IX

Conditions
ConditionsYield
With ammonium hydroxide; phosphoric acid tributyl ester; sulfuric acid In benzene at 40℃; for 1.5h;
methanol
67-56-1

methanol

protoporphyrin IX
553-12-8

protoporphyrin IX

protoporphyrin IX dimethyl ester
5522-66-7

protoporphyrin IX dimethyl ester

Conditions
ConditionsYield
With sulfuric acid at -10℃; for 18h;95%
protoporphyrin IX
553-12-8

protoporphyrin IX

N-(2-aminoethyl)maleimide trifluoroacetate

N-(2-aminoethyl)maleimide trifluoroacetate

C46H46N8O6

C46H46N8O6

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 0 - 20℃; for 4h;
Stage #2: N-(2-aminoethyl)maleimide trifluoroacetate In N,N-dimethyl-formamide at 20℃; for 5h;
73%
methanol
67-56-1

methanol

protoporphyrin IX
553-12-8

protoporphyrin IX

20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid tert-butyl ester
297162-50-6

20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid tert-butyl ester

C54H71N5O12

C54H71N5O12

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide Inert atmosphere;
Stage #2: methanol With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride
Stage #3: 20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid tert-butyl ester Further stages;
72%
rac-5-(2-hydroxyl(cyclohexylethyl))-5H-imidazo[5,1-a]isoindole
1402836-58-1

rac-5-(2-hydroxyl(cyclohexylethyl))-5H-imidazo[5,1-a]isoindole

protoporphyrin IX
553-12-8

protoporphyrin IX

C52H54N6O4

C52H54N6O4

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 60℃; for 5h;65.8%
protoporphyrin IX
553-12-8

protoporphyrin IX

tert-butyl alcohol
75-65-0

tert-butyl alcohol

3-[(1Z,5Z,9Z,14Z)-18-(2-tert-Butoxycarbonyl-ethyl)-3,7,12,17-tetramethyl-8,13-divinyl-22,24-dihydro-porphin-2-yl]-propionic acid

3-[(1Z,5Z,9Z,14Z)-18-(2-tert-Butoxycarbonyl-ethyl)-3,7,12,17-tetramethyl-8,13-divinyl-22,24-dihydro-porphin-2-yl]-propionic acid

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With dmap; di-tert-butyl dicarbonate In pyridine at 20℃; for 6h;
Stage #2: tert-butyl alcohol In pyridine at 20℃; for 1h; Further stages.;
64%
With pyridine; dmap at 20℃;64%
2-[2-(2-azidoethoxy)ethoxy]ethanol
86520-52-7

2-[2-(2-azidoethoxy)ethoxy]ethanol

protoporphyrin IX
553-12-8

protoporphyrin IX

C40H45N7O6

C40H45N7O6

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 0 - 20℃;58%
protoporphyrin IX
553-12-8

protoporphyrin IX

benzyl alcohol
100-51-6

benzyl alcohol

A

6-[2'-(benzyloxycarbonyl)ethyl]-7-(2'-carboxyethyl)-1,3,5,8-tetramethyl-2,4-divinylporphyrin

6-[2'-(benzyloxycarbonyl)ethyl]-7-(2'-carboxyethyl)-1,3,5,8-tetramethyl-2,4-divinylporphyrin

B

3-[(5Z,10Z,14Z,19Z)-18-(2-Benzyloxycarbonyl-ethyl)-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl]-propionic acid benzyl ester

3-[(5Z,10Z,14Z,19Z)-18-(2-Benzyloxycarbonyl-ethyl)-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl]-propionic acid benzyl ester

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With pyridine; pivaloyl chloride; triethylamine In dichloromethane at -5℃;
Stage #2: benzyl alcohol In dichloromethane at 5 - 8℃; for 12h;
A 47%
B 18%
metronidazole
443-48-1

metronidazole

protoporphyrin IX
553-12-8

protoporphyrin IX

2,7,12,18-tetramethyl-13,17-bis[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxycarbonylethyl]-3,8-divinyloporphyrin

2,7,12,18-tetramethyl-13,17-bis[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxycarbonylethyl]-3,8-divinyloporphyrin

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 48h;29%
methanol
67-56-1

methanol

Glycyl-L-(1-methyl)histidinemethyl ester

Glycyl-L-(1-methyl)histidinemethyl ester

protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-methoxycarbonyl)ethyl-12-(2-((O-methyl)(1-methyl)histidyl)glycineamideethyl)-2,7,13,17-tetramethyl-porphyrin

3,18-divinyl-8-(3-methoxycarbonyl)ethyl-12-(2-((O-methyl)(1-methyl)histidyl)glycineamideethyl)-2,7,13,17-tetramethyl-porphyrin

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With pyridine; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate at 20℃; for 0.333333h;
Stage #2: Glycyl-L-(1-methyl)histidinemethyl ester In N,N-dimethyl-formamide at 20℃; for 2.5h;
Stage #3: methanol In N,N-dimethyl-formamide for 18h;
25%
3-(1H-imidazol-1-yl)propan-1-amine
5036-48-6

3-(1H-imidazol-1-yl)propan-1-amine

protoporphyrin IX
553-12-8

protoporphyrin IX

methylamine
74-89-5

methylamine

3,18-divinyl-8-(3-methylamido)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-methylamido)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
Stage #1: protoporphyrin IX With triethylamine In pyridine for 0.166667h;
Stage #2:
Stage #3: 3-(1H-imidazol-1-yl)propan-1-amine; methylamine With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate more than 3 stages;
19%
protoporphyrin IX
553-12-8

protoporphyrin IX

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7,12-diformyl-3,8,13,17-tetramethyl-porphyrin-2-yl]-propionic acid
60185-98-0

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7,12-diformyl-3,8,13,17-tetramethyl-porphyrin-2-yl]-propionic acid

Conditions
ConditionsYield
With oxygen; 2,4-dichlorophenoxyacetic acid dimethylamine Mechanism; Irradiation; other porphyrine derivatives, influence of solvents;
With oxygen; 2,4-dichlorophenoxyacetic acid dimethylamine Irradiation;
protoporphyrin IX
553-12-8

protoporphyrin IX

A

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7,12-diformyl-3,8,13,17-tetramethyl-porphyrin-2-yl]-propionic acid
60185-98-0

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7,12-diformyl-3,8,13,17-tetramethyl-porphyrin-2-yl]-propionic acid

B

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7-formyl-3,8,13,17-tetramethyl-12-vinyl-porphyrin-2-yl]-propionic acid
89398-64-1

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-7-formyl-3,8,13,17-tetramethyl-12-vinyl-porphyrin-2-yl]-propionic acid

C

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-12-formyl-3,8,13,17-tetramethyl-7-vinyl-porphyrin-2-yl]-propionic acid
10200-02-9

3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-12-formyl-3,8,13,17-tetramethyl-7-vinyl-porphyrin-2-yl]-propionic acid

D

3-{(1Z,5Z,9Z,14Z)-18-(2-Carboxy-ethyl)-7-hydroxy-3,7,12,17-tetramethyl-8-[2-oxo-eth-(Z)-ylidene]-13-vinyl-7,8,22,24-tetrahydro-porphin-2-yl}-propionic acid
89398-63-0

3-{(1Z,5Z,9Z,14Z)-18-(2-Carboxy-ethyl)-7-hydroxy-3,7,12,17-tetramethyl-8-[2-oxo-eth-(Z)-ylidene]-13-vinyl-7,8,22,24-tetrahydro-porphin-2-yl}-propionic acid

E

3-{(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-8-hydroxy-3,8,13,17-tetramethyl-7-[2-oxo-eth-(Z)-ylidene]-12-vinyl-7,8,21,23-tetrahydro-porphin-2-yl}-propionic acid
70552-66-8

3-{(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-8-hydroxy-3,8,13,17-tetramethyl-7-[2-oxo-eth-(Z)-ylidene]-12-vinyl-7,8,21,23-tetrahydro-porphin-2-yl}-propionic acid

Conditions
ConditionsYield
With oxygen In benzene for 2.5h; Product distribution; Mechanism; Irradiation; var. environment, time;
protoporphyrin IX
553-12-8

protoporphyrin IX

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

C42H38N8O6

C42H38N8O6

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 0.333333h;
protoporphyrin IX
553-12-8

protoporphyrin IX

cyclomaltooctaose
17465-86-0

cyclomaltooctaose

C48H80O40*C34H34N4O4

C48H80O40*C34H34N4O4

Conditions
ConditionsYield
With sodium hydroxide at 20℃; complex formation;
protoporphyrin IX
553-12-8

protoporphyrin IX

alpha cyclodextrin
10016-20-3

alpha cyclodextrin

C36H60O30*C34H34N4O4

C36H60O30*C34H34N4O4

Conditions
ConditionsYield
With sodium hydroxide at 20℃; complex formation;
protoporphyrin IX
553-12-8

protoporphyrin IX

3,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropoyl chloride

3,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropoyl chloride

Conditions
ConditionsYield
With oxalyl dichloride In dichloromethane for 1h; Heating;
With oxalyl dichloride for 0.5h; Reflux; Inert atmosphere;
protoporphyrin IX
553-12-8

protoporphyrin IX

harderoporphyrinogen IX
7412-77-3

harderoporphyrinogen IX

Conditions
ConditionsYield
With sodium amalgam
With sodium amalgam
3-(1H-imidazol-1-yl)propan-1-amine
5036-48-6

3-(1H-imidazol-1-yl)propan-1-amine

protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-carboxy)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-carboxy)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
With pyridine; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate at 20 - 40℃; for 4.5h;
4-(N-(2-methylimidazolyl))butylamine
88940-40-3

4-(N-(2-methylimidazolyl))butylamine

protoporphyrin IX
553-12-8

protoporphyrin IX

3-((1Z,5Z,9Z,14Z)-3,7,12,17-Tetramethyl-18-{2-[4-(2-methyl-imidazol-1-yl)-butylcarbamoyl]-ethyl}-8,13-divinyl-22,24-dihydro-porphin-2-yl)-propionic acid

3-((1Z,5Z,9Z,14Z)-3,7,12,17-Tetramethyl-18-{2-[4-(2-methyl-imidazol-1-yl)-butylcarbamoyl]-ethyl}-8,13-divinyl-22,24-dihydro-porphin-2-yl)-propionic acid

Conditions
ConditionsYield
With pyridine; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate at 20 - 40℃; for 0.075h;
protoporphyrin IX
553-12-8

protoporphyrin IX

O-methyl-L-histydyl-glycine
106461-07-8

O-methyl-L-histydyl-glycine

(S)-2-(2-{3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl]-propionylamino}-acetylamino)-3-(3H-imidazol-4-yl)-propionic acid methyl ester

(S)-2-(2-{3-[(5Z,10Z,14Z,19Z)-18-(2-Carboxy-ethyl)-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl]-propionylamino}-acetylamino)-3-(3H-imidazol-4-yl)-propionic acid methyl ester

Conditions
ConditionsYield
With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate In N,N-dimethyl-formamide at 20 - 40℃; for 4.5h;
protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-methoxycarbonyl)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-methoxycarbonyl)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: pyridine; BOP / 4.5 h / 20 - 40 °C
2: 75 mg / 12 h / 40 °C
View Scheme
protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-methylamido)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-methylamido)ethyl-12-(3-(N-imidazolyl)propylamido)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: pyridine; BOP / 4.5 h / 20 - 40 °C
2: 12 h / 40 °C
View Scheme
protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-ethoxycarbonyl)ethyl-12-(4-(N-(2-methylimidazolyl))butylamido)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-ethoxycarbonyl)ethyl-12-(4-(N-(2-methylimidazolyl))butylamido)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: BOP; pyridine / 0.07 h / 20 - 40 °C
2: 12 h / 40 °C
View Scheme
protoporphyrin IX
553-12-8

protoporphyrin IX

3,18-divinyl-8-(3-ethoxycarbonyl)ethyl-12-(((3-N-glycyl-L-histidinyl)-9-oxymethyl)carbonyl)ethyl-2,7,13,17-tetramethylporphyrin

3,18-divinyl-8-(3-ethoxycarbonyl)ethyl-12-(((3-N-glycyl-L-histidinyl)-9-oxymethyl)carbonyl)ethyl-2,7,13,17-tetramethylporphyrin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: BOP / dimethylformamide / 4.5 h / 20 - 40 °C
2: 12 h / 40 °C
View Scheme
protoporphyrin IX
553-12-8

protoporphyrin IX

3-(18-{2-[2-(7,8-dimethyl-2,4-dioxo-3,4-dihydro-2H-benzo[g]pteridin-10-yl)-ethylcarbamoyl]-ethyl}-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl)-propionic acid tert-butyl ester

3-(18-{2-[2-(7,8-dimethyl-2,4-dioxo-3,4-dihydro-2H-benzo[g]pteridin-10-yl)-ethylcarbamoyl]-ethyl}-3,8,13,17-tetramethyl-7,12-divinyl-porphyrin-2-yl)-propionic acid tert-butyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: DMAP; (Boc)2O / pyridine / 6 h / 20 °C
1.2: 64 percent / pyridine / 1 h / 20 °C
2.1: 72 percent / DPPA; Et3N / dimethylformamide / 11 h / 20 °C
View Scheme
protoporphyrin IX
553-12-8

protoporphyrin IX

4-bis(2-hydroxyethyl)-6,7-bis[2-(methoxycarbonyl)ethyl]-1,3,5,8-tetramethylporphyrin
33070-12-1

4-bis(2-hydroxyethyl)-6,7-bis[2-(methoxycarbonyl)ethyl]-1,3,5,8-tetramethylporphyrin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 95 percent / 5 percent H2SO4 / 18 h / -10 °C
2.1: Tl(NO3)3*3H2O; MeOH
2.2: HCOOH
2.3: NaBH4
View Scheme

553-12-8Relevant academic research and scientific papers

A point mutation of valine-311 to methionine in Bacillus subtilis protoporphyrinogen oxidase does not greatly increase resistance to the diphenyl ether herbicide oxyfluorfen

Jeong, Eunjoo,Houn, Thavrak,Kuk, Yongin,Kim, Eun-Seon,Chandru, Hema Kumar,Baik, Myunggi,Back, Kyoungwhan,Guh, Ja-Ock,Han, Oksoo

, p. 389 - 397 (2003)

In an effort to asses the effect of Val311Met point mutation of Bacillus subtilis protoporphyrinogen oxidase on the resistance to diphenyl ether herbicides, a Val311Met point mutant of B. subtilis protoporphyrinogen oxidase was prepared, heterologously expressed in Escherichia coli, and the purified recombinant Val311Met mutant protoporphyrinogen oxidase was kinetically characterized. The mutant protoporphyrinogen oxidase showed very similar kinetic patterns to wild type protoporphyrinogen oxidase, with slightly decreased activity dependent on pH and the concentrations of NaCl, Tween 20, and imidazole. When oxyfluorfen was used as a competitive inhibitor, the Val311Met mutant protoporphyrinogen oxidase showed an increased inhibition constant about 1.5 times that of wild type protoporphyrinogen oxidase. The marginal increase of the inhibition constant indicates that the Val311Met point mutation in B. subtilis protoporphyrinogen oxidase may not be an important determinant in the mechanism that protects protoporphyrinogen oxidase against diphenyl ether herbicides.

Self-Sensitized Photooxidation of Protoporphyrin IX Derivatives in Aqueous Surfactant Solutions: Product and Mechanistic Studies

Cox, G. Sidney,Krieg, Marianne,Whitten, David G.

, p. 6930 - 6937 (1982)

The photooxidation of protoporphyrin IX and its dimethyl ester has been investigated in several aqueous surfactant media including neutral micelles (Brij 35) and vesicles (dipalmitoylphosphatidylcholine) and charged micelles (SDS and DTAB).The results obtained indicate that while the same products are formed in these media as in homogeneous organic solvents such as methylene chloride, the product distributions are quite different.At least two major reaction paths are indicated.The first involves singlet oxygen generation and attack on ground-state porphyrins.This path can be shown by studies with H2O vs.D2O and the use of the aqueous phase quencher N3- to consist of two components, an intramicellar path and an intermicellar reaction.The second path appears most likely to involve electron transfer from excited porphyrin to generate superoxide and porphyrin ?-cation.This path appears to be exclusively intramicellar and is much more prominent in the organized media than in homogeneous solution.Quenching of 1O2* by azide appears to enhance the "superoxide-derived" products in SDS and Brij 35 supporting recent studies indicating that azide quenching occurs at least in part of electron transfer.

Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease

Wang, Nan,Jin, Xin,Guo, Dongbo,Tong, Gangsheng,Zhu, Xinyuan

, p. 461 - 474 (2017)

Iron accumulation in substantia nigra pars compacta (SNpc) has been proved to be a prominent pathophysiological feature of Parkinson’s diseases (PD), which can induce the death of dopaminergic (DA) neurons, up-regulation of reactive oxygen species (ROS), and further loss of motor control. In recent years, iron chelation therapy has been demonstrated to be an effective treatment for PD, which has shown significant improvements in clinical trials. However, the current iron chelators are suboptimal due to their short circulation time, side effects, and lack of proper protection from chelation with ions in blood circulation. In this work, we designed and constructed iron chelation therapeutic nanoparticles protected by a zwitterionic poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) to delay the saturation of iron chelators in blood circulation and prolong the in vivo lifetime, with HIV-1 trans-activating transcriptor (TAT) served as a shuttle to enhance the blood-brain barrier (BBB) permeability. We explored and investigated whether the Parkinsonian neurodegeneration and the corresponding symptoms in behaviors and physiologies could be prevented or reversed both in vitro and in vivo. The results demonstrated that iron chelator loaded therapeutic nanoparticles could reverse functional deficits in Parkinsonian mice not only physiologically but also behaviorally. On the contrary, both untreated PD mice and non-TAT anchored nanoparticle treated PD mice showed similar loss in DA neurons and difficulties in behaviors. Therefore, with protection of zwitterionic polymer and prolonged in vivo lifetime, iron chelator loaded nanoparticles with delayed saturation provide a PD phenotype reversion therapy and significantly improve the living quality of the Parkinsonian mice.

On the Nature of 'Haematoporphyrin Derivative'

Bonnett, Raymond,Ridge, Richard J.,Scourides, Panayiotis A.,Berenbaum, Morris C.

, p. 3135 - 3140 (1981)

The components of haematoporphyrin derivative ( a preparation used as a photosensitiser in clinical applications, and made by treating haematoporphyrin with sulphuric acid-acetic acid) have been separated by preparative h.p.l.c. and identified by comparison with authentic porphyrincarboxylic acids.The composition of the mixture is somewhat variable but the main components are O,O'-diacetylhaematoporphyrin (6) and O-acetylhaematoporphyrin (2)/(3) with smaller amounts of the 8(3)-(1-acetoxyethyl)-3(8)-vinyldeuteroporphyrin isomers (7) and (8) and the corresponding alcohols (4) and (5).

Quantitative structural insight into human variegate porphyria disease

Wang, Baifan,Wen, Xin,Qin, Xiaohong,Wang, Zhifang,Tan, Ying,Shen, Yuequan,Xi, Zhen

, p. 11731 - 11740 (2013)

Defects in the human protoporphyrinogen oxidase (hPPO) gene, resulting in ~ 50% decreased activity of hPPO, is responsible for the dominantly inherited disorder variegate porphyria (VP). To understand the molecular mechanism of VP, we employed the sitedirected mutagenesis, biochemical assays, structural biology, and molecular dynamics simulation studies to investigate VP-causing hPPO mutants. We report here the crystal structures of R59Q and R59G mutants in complex with acifluorfen at a resolution of 2.6 and 2.8 A. The r.m.s.d. of the Cα atoms of the active site structure of R59G and R59Q with respect to the wild-type was 0.20 and 0.15 A, respectively. However, these highly similar static crystal structures of mutants with the wild-type could not quantitatively explain the observed large differences in their enzymatic activity. To understand how the hPPO mutations affect their catalytic activities, we combined molecular dynamics simulation and statistical analysis to quantitatively understand the molecular mechanism of VP-causing mutants. We have found that the probability of the privileged conformations of hPPO can be correlated very well with the kcat/Km of PPO (correlation coefficient, R2 > 0.9), and the catalytic activity of 44 clinically reported VP-causing mutants can be accurately predicted. These results indicated that the VP-causing mutation affect the catalytic activity of hPPO by affecting the ability of hPPO to sample the privileged conformations. The current work, together with our previous crystal structure study on the wild-type hPPO, provided the quantitative structural insight into human variegate porphyria disease.

Haematoporphyrin Derivative

Bonnett, Raymond,Ridge, Richard J.,Scourides, Panayiotis A.,Berenbaum, Morris C.

, p. 1198 - 1199 (1980)

Components of 'haematoporphyrin derivative,' a photosensitiser employed in clinical studies, have been separated as the free acids by reverse-phase high pressure liquid chromatography, and identified, the major components being O,O'-diacetylhaematoporphyrin and O-acetylhaematoporphyrin.

ROMP polymer supported manganese porphyrins: Influence of C[dbnd]C bonds along polymer chains on catalytic behavior in oxidation of low concentration Fe2+

Li, Fanfan,Wang, Xuan,Zhang, Yanwu,Zhao, Huanhuan

, (2020/02/22)

One unsaturated polymer support was prepared through ring opening metathesis polymerization (ROMP) of norbornene-2,3-dip-toluene sulfonate initiated by Grubbs 2nd initiator and manganese porphyrins were immobilized on polymer through transesterification reaction. To investigate the effect of C[dbnd]C bonds along polymer chains on the catalytic behavior, the obtained polymer supported catalyst (P-PPIXMnCl) was applied in oxidation of low concentration Fe2+ to mimic catalytic behavior of Ceruloplasmin. In the presence of P-PPIXMnCl, the conversion of Fe2+ reaches to 91.92% and 96.46% at 10 °C and 37.5 °C (body temperature), respectively. Compared to manganese porphyrins, P-PPIXMnCl can dramatically increase oxidation rate of Fe2+ and the catalytic kinetic shows that the oxidation reaction changes from second-order to third-order. Upon hydrogenation of ROMP polymer, the oxidation reaction still conforms to the second-order kinetics. Density functional theory (DFT) calculation shows that the C[dbnd]C bonds along polymer chains play an important role in the coordination with Fe2+ in the catalytic microenvironment. The real time morphology of supported catalysts in aqueous environment characterized by Cryo-TEM indicates that hydrogenation can shrink the morphology of polymer-water skeleton. The catalyst could be recycled six times without any significant loss in activity. The liner heterogeneous catalyst is expected to be used as drugs for treating excessive iron accumulation in the human body.

Handling heme: The mechanisms underlying the movement of heme within and between cells

Donegan, Rebecca K.,Moore, Courtney M.,Hanna, David A.,Reddi, Amit R.

, p. 88 - 100 (2018/08/21)

Heme is an essential cofactor and signaling molecule required for virtually all aerobic life. However, excess heme is cytotoxic. Therefore, heme must be safely transported and trafficked from the site of synthesis in the mitochondria or uptake at the cell surface, to hemoproteins in most subcellular compartments. While heme synthesis and degradation are relatively well characterized, little is known about how heme is trafficked and transported throughout the cell. Herein, we review eukaryotic heme transport, trafficking, and mobilization, with a focus on factors that regulate bioavailable heme. We also highlight the role of gasotransmitters and small molecules in heme mobilization and bioavailability, and heme trafficking at the host-pathogen interface.

Revisiting the Mechanism of the Anaerobic Coproporphyrinogen III Oxidase HemN

Ji, Xinjian,Mo, Tianlu,Liu, Wan-Qiu,Ding, Wei,Deng, Zixin,Zhang, Qi

supporting information, p. 6235 - 6238 (2019/04/04)

HemN is a radical S-adenosyl-l-methionine (SAM) enzyme that catalyzes the oxidative decarboxylation of coproporphyrinogen III to produce protoporphyrinogen IX, an intermediate in heme biosynthesis. HemN binds two SAM molecules in the active site, but how these two SAMs are utilized for the sequential decarboxylation of the two propionate groups of coproporphyrinogen III remains largely elusive. Provided here is evidence showing that in HemN catalysis a SAM serves as a hydrogen relay which mediates a radical-based hydrogen transfer from the propionate to the 5′-deoxyadenosyl (dAdo) radical generated from another SAM in the active site. Also observed was an unexpected shunt product resulting from trapping of the SAM-based methylene radical by the vinyl moiety of the mono-decarboxylated intermediate, harderoporphyrinogen. These results suggest a major revision of the HemN mechanism and reveal a new paradigm of the radical-mediated hydrogen transfer in radical SAM enzymology.

TARGETED ANTIMICROBIAL PHOTODYNAMIC THERAPY

-

Paragraph 0177, (2019/10/29)

The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 553-12-8